Very good point. I will add though that the efficacy rate of the Pfizer/BioNTech vaccine is better than the Chinese vaccines (due to utilising better and modern technology).
This is not true. No evidence to support your conclusion. None of the vaccines were done together in phase III trials , so their efficacy rates are not comparable to each other.
I will note though, that efficacy is not the only statistic by which a vaccine is rated as better or worse than another vaccine.
Agreed. The AP1000 should have been only used for getting experience and technology. After that China should have abandoned it and went 100% for domestic technology and IP.
Ideally these kind of decisions should be taken like these:
For example you would rate the AP1000 best for pure profit reasons, and for the least risk (already developed).
Then you would include criteria such as domestic production(IP, tech etc), national security etc.
And then the different ministries and agencies would conclude what is more important and choose how high each critiria should be categorized.
E.g you could say that National Security is A+, Domestic IP A, Commercial B- etc.
Thats how contracts and decisions should be taken.